Mounjaro Injection Site Reactions That Don't Go Away: When to Worry and What to Do

What the Mounjaro label says about injection site reactions

Mounjaro is tirzepatide, a once-weekly subcutaneous injection used with diet and exercise to improve blood sugar in adults and in children 10 years and older with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk for them [1].

The label reports injection site reactions in 3.2% of Mounjaro-treated adults versus 0.4% of placebo-treated adults in its pool of placebo-controlled trials. They are not in the label's table of reactions reported by at least 5% of treated patients, which lists nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain [1]. That table comes from two placebo-controlled trials, SURPASS-1 and SURPASS-5, with a mean exposure of 36.6 weeks [1].

A 2026 systematic review and network meta-analysis of 24 phase 3 trials in adults with overweight or obesity found tirzepatide was associated with a higher risk of injection site reactions than the comparators it was measured against [3].

Serious hypersensitivity versus a local reaction

The Mounjaro label warns that serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported [1]. When one is suspected, the label says to discontinue Mounjaro, treat promptly per standard of care and monitor until signs and symptoms resolve [1]. A known serious hypersensitivity to tirzepatide or to any excipient in Mounjaro is a contraindication [1]. The label also advises caution in people who have had angioedema or anaphylaxis with another GLP-1 receptor agonist, because it is unknown whether they are predisposed to the same reactions with Mounjaro [1].

The label lists injection site reactions and hypersensitivity reactions as separate adverse reactions; hypersensitivity reactions were reported in 3.2% of Mounjaro-treated adults versus 1.7% on placebo [1].

Anti-drug antibodies and injection site reactions

Across seven phase 3 trials, 51.1% of 5,025 tirzepatide-treated adults with type 2 diabetes developed treatment-emergent anti-tirzepatide antibodies [2]. Neutralizing antibodies against tirzepatide activity at the GIP and GLP-1 receptors were detected in 1.9% and 2.1% of patients, and fewer than 1.0% had cross-reactive neutralizing antibodies against the body's own GIP or GLP-1 [2]. Injection site reactions were reported more often by people who developed antibodies (4.6% of antibody-positive versus 0.7% of antibody-negative adults in the label's seven-trial pool), but most events were nonserious and nonsevere, and most occurred or resolved regardless of antibody status or titer [1][2]. Antibody status had no effect on the drug's pharmacokinetics or efficacy [2]. That is an association measured across trial populations [2].

A lump that will not go away

A study of 430 outpatients injecting insulin found lipohypertrophy, a localized thickening of fatty tissue, in 64.4% of them [4]. Of the patients who correctly rotated sites, only 5% had it, and 98% of those with lipohypertrophy either did not rotate sites or rotated incorrectly; reusing needles more than 5 times was also linked to higher risk [4]. That study was in people injecting insulin, not Mounjaro. The Mounjaro label says to rotate injection sites with each dose [1].

What the label says about giving the injection

The Mounjaro label lists the abdomen and the thigh as injection sites, or the back of the upper arm when another person gives the injection, and says to rotate sites with each dose [1]. The drug can be given at any time of day, with or without meals [1]. The label says it should appear clear and colorless to slightly yellow, and should not be used if particulate matter or discoloration is seen [1]. A KwikPen should never be shared between patients, even if the needle is changed [1].